Histogen - Regenerative medicine company based on naturally made products

Restoring Function & Enhancing Lives

Histogen is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.

ABOUT

clinical programs

Histogen is advancing three clinical programs in therapeutic indications with large commercial market opportunities:

Hair Growth

A minimally-invasive treatment that is intended to grow new hair, not simply preserve existing hair.

Dermal Fillers

Human-derived collagen and extracellular matrix dermal fillers delivering potentially longer-lasting effects with fewer side effects for the treatment of facial folds and wrinkles.

Joint Cartilage Repair

Histogen’s extracellular matrix for articular cartilage defects regenerates hyaline cartilage for the treatment of knee osteoarthritis with a novel malleable scaffold produced by the body’s own stem cells.

Latest News

October 19, 2020

Histogen Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations

SAN DIEGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced the

October 5, 2020

Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men

Top Line Results Remain on Track for Q4’2020 SAN DIEGO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy

September 29, 2020

Histogen Announces Update for its HST-002 Dermal Filler Program

HST-002 Designated as Drug-Biologic-Device Combination Product HST -001 1b/2a Trial f or Androgenic Alopecia i n Men o n Track f or Top Line Data Results i n 4Q20 HST -003 IND Submission f or Regeneration o f Cartilage i n t he Knee Expected 4Q20 SAN DIEGO, Sept.